Subacute sclerosing panencephalitis: An update

Developmental Medicine and Child Neurology

Volumn 52, Issue 10, 2010, Pages 901-907

  Gutierrez, Jose ^a   Issacson, Richard S ^a   Koppel, Barbara S ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b METROPOLITAN HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; METHISOPRINOL; RIBAVIRIN;

ANEMIA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ELECTROENCEPHALOGRAM; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; MEASLES; MEASLES VACCINATION; MUCOSA INFLAMMATION; MYOCLONUS SEIZURE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL MUCOSITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; SEROLOGY; SOMNOLENCE; SUBACUTE SCLEROSING PANENCEPHALITIS; SURVIVAL RATE;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; APOPTOSIS; BRAIN; DEMYELINATING DISEASES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSIES, MYOCLONIC; FEMALE; GLIOSIS; HUMANS; INOSINE PRANOBEX; INTERFERON-ALPHA; MAGNETIC RESONANCE IMAGING; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SUBACUTE SCLEROSING PANENCEPHALITIS; TIME FACTORS; VIRION;

EID: 77956477069     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2010.03717.x     Document Type: Review

References (63)

1. Tomoda A, Nomura K, Shiraishi S. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan. Brain Dev 2003, 25:514-7.
2. Dawson JR. Cellular inclusions in cerebral lesions of epidemic encephalitis. Arch Neurol Psychiatry 1934, 31:685-700.
3. van Bogaert L. Une leuco-encephalite sclerosante subaigue. J Neurol Neurosurg Psychiatry 1945, 8:101-20.
4. Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin 1985, 3:179-96.
5. Tomoda A, Miike T, Miyagawa S, Negi A, Takeshima H. Subacute sclerosing panencephalitis and chorioretinitis. Brain Dev 1997, 19:55-7.
6. Tuncay R, Akman-Demir G, Gokyigit A. MRI in subacute sclerosing panencephalitis. Neuroradiology 1996, 38:636-40.
7. Singer C, Lang AE, Suchowersky O. Adult-onset subacute sclerosing panencephalitis: case reports and review of the literature. Mov Disord 1997, 12:342-53.
8. Anlar B, Kose G, Gurer Y, Altunbasak S, Haspolat S, Okan M. Changing epidemiological features of subacute sclerosing panencephalitis. Infection 2001, 29:192-5.
9. Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007, 36:1334-48.
10. Campbell C, Levin S, Humphreys P, Walop W, Brannan R. Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatr 2005, 5:47.
11. Zilber N, Kahana E. Environmental risk factors for subacute sclerosing panencephalitis (SSPE). Acta Neurol Scand 1998, 98:49-54.
12. Hassan A, Lily O, Johnson M, Al-Din A. Adult onset SSPE: experiences in West Yorkshire over a 12 month period. J Neurol Neurosurg Psychiatry 2005, 76:1310-1.
13. Modlin JF, Jabbour JT, Witte JJ, Halsey NA. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics 1977, 59:505-12.
14. Manayani DJ, Abraham M, Gnanamuthu C, Solomon T, Alexander M, Sridharan G. SSPE - The continuing challenge: a study based on serological evidence from a teritary care centre in India. Indian J Med Microbiol 2002, 20:16-8.
15. Herguner MO, Altunbasak S, Baytok V. Patients with acute, fulminant form of SSPE. Turk J Pediatr 2007, 49:422-5.
16. Akram M, Naz F, Malik A, Hamid H. Clinical profile of subacute sclerosing panencephalitis. J Coll Physicians Surg Pak 2008, 18:485-8.
17. Koppel BS, Poon TP, Khandji A, Pavlakis SG, Pedley TA. Subacute sclerosing panencephalitis and acquired immunodeficiency syndrome: role of electroencephalography and magnetic resonance imaging. J Neuroimaging 1996, 6:122-5.
18. Dyken PR, Cunningham SC, Ward LC. Changing character of subacute sclerosing panencephalitis in the United States. Pediatr Neurol 1989, 5:339-41.
19. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 1998, 19:435-54.
20. Prashanth LK, Taly AB, Ravi V, Sinha S, Arunodaya GR. Adult onset subacute sclerosing panencephalitis: clinical profile of 39 patients from a tertiary care centre. J Neurol Neurosurg Psychiatry 2006, 77:630-3.
21. Tuxhorn IE. Familial subacute sclerosing panencephalitis in two siblings. Pediatr Neurol 2004, 31:291-4.
22. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis 1994, 170(Suppl. 1):S24-31.
23. Inoue T, Kira R, Nakao F. Contribution of the interleukin 4 gene to susceptibility to subacute sclerosing panencephalitis. Arch Neurol 2002, 59:822-7.
24. Yentur SP, Gurses C, Demirbilek V. Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. J Neuroimmunol 2005, 170:179-85.
25. Hara T, Yamashita S, Aiba H. Measles virus-specific T helper 1/T helper 2-cytokine production in subacute sclerosing panencephalitis. J Neurovirol 2000, 6:121-6.
26. Nagano I, Nakamura S, Yoshioka M, Onodera J, Kogure K, Itoyama Y. Expression of cytokines in brain lesions in subacute sclerosing panencephalitis. Neurology 1994, 44:710-5.
27. Pipo-Deveza JR, Kusuhara K, Silao CL. Analysis of MxA, IL-4, and IRF-1 genes in Filipino patients with subacute sclerosing panencephalitis. Neuropediatrics 2006, 37:222-8.
28. Makhortova NR, Askovich P, Patterson CE, Gechman LA, Gerard NP, Rall GF. Neurokinin-1 enables measles virus trans-synaptic spread in neurons. Virology 2007, 362:235-44.
29. Shimizu T, Matsuishi T, Iwamoto R. Elevated levels of anti-CD9 antibodies in the cerebrospinal fluid of patients with subacute sclerosing panencephalitis. J Infect Dis 2002, 185:1346-50.
30. Cattaneo R, Schmid A, Rebmann G. Accumulated measles virus mutations in a case of subacute sclerosing panencephalitis: interrupted matrix protein reading frame and transcription alteration. Virology 1986, 154:97-107.
31. Hirano A, Wang AH, Gombart AF, Wong TC. The matrix proteins of neurovirulent subacute sclerosing panencephalitis virus and its acute measles virus progenitor are functionally different. Proc Natl Acad Sci USA 1992, 89:8745-9.
32. Schmid A, Spielhofer P, Cattaneo R, Baczko K, ter Meulen V, Billeter MA. Subacute sclerosing panencephalitis is typically characterized by alterations in the fusion protein cytoplasmic domain of the persisting measles virus. Virology 1992, 188:910-5.
33. Kuhne Simmonds M, Brown DW, Jin L. Measles viral load may reflect SSPE disease progression. Virol J 2006, 3:49.
34. Hayashi M, Arai N, Satoh J. Neurodegenerative mechanisms in subacute sclerosing panencephalitis. J Child Neurol 2002, 17:725-30.
35. Gutierrez J, Koppel B, Kleiman A, Akfirat G. Multiple sclerosis and Epstein-Barr virus: a growing association. Rev Med Inst Mex Seguro Soc 2008, 46:639-42.
36. Lewandowska E, Lechowicz W, Szpak GM, Sobczyk W. Quantitative evaluation of intranuclear inclusions in SSPE: correlation with disease duration. Folia Neuropathol 2001, 39:237-41.
37. Gascon GG. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol 2003, 18:819-27.
38. Prashanth LK, Taly AB, Ravi V, Sinha S, Rao S. Long term survival in subacute sclerosing panencephalitis: an enigma. Brain Dev 2006, 28:447-52.
39. Jabbour JT, Garcia JH, Lemmi H, Ragland J, Duenas DA, Sever JL. Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases. JAMA 1969, 207:2248-54.
40. Oga T, Ikeda A, Nagamine T. Implication of sensorimotor integration in the generation of periodic dystonic myoclonus in subacute sclerosing panencephalitis (SSPE). Mov Disord 2000, 15:1173-83.
41. Dyken PR, Swift A, DuRant RH. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol 1982, 11:359-64.
42. Bradley WG. Neurology in clinical practice 2008, 5th edn, Philadelphia, PA, Butterworth-Heinemann/Elsevier
43. Lakshmi V, Malathy Y, Rao RR. Serodiagnosis of subacute sclerosing panencephalitis by enzyme linked immunosorbent assay. Indian J Pediatr 1993, 60:37-41.
44. Mehta PD, Kulczycki J, Mehta SP. Increased levels of beta 2-microglobulin, soluble interleukin-2 receptor, and soluble CD8 in patients with subacute sclerosing panencephalitis. Clin Immunol Immunopathol 1992, 65:53-9.
45. Praveen-kumar S, Sinha S, Taly AB. Electroencephalographic and imaging profile in a subacute sclerosing panencephalitis (SSPE) cohort: a correlative study. Clin Neurophysiol 2007, 118:1947-54.
46. Kurata T, Matsubara E, Yokoyama M, Nagano I, Shoji M, Abe K. Improvement of SSPE by intrathecal infusion of alpha-IFN. Neurology 2004, 63:398-9.
47. Ekmekci O, Karasoy H, Gokcay A, Ulku A. Atypical EEG findings in subacute sclerosing panencephalitis. Clin Neurophysiol 2005, 116:1762-7.
48. Murata R, Matsuoka O, Nakajima S. Serial magnetic resonance imaging in subacute sclerosing panencephalitis. Jpn J Psychiatry Neurol 1987, 41:277-81.
49. Miyazaki M, Nishimura M, Toda Y, Saijo T, Mori K, Kuroda Y. Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon alpha. Brain Dev 2005, 27:301-3.
50. Oguz KK, Celebi A, Anlar B. MR imaging, diffusion-weighted imaging and MR spectroscopy findings in acute rapidly progressive subacute sclerosing panencephalitis. Brain Dev 2007, 29:306-11.
51. Risk WS, Haddad FS. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East. Arch Neurol 1979, 36:610-4.
52. Gascon G, Yamani S, Crowell J. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993, 15:346-55.
53. Yalaz K, Anlar B, Oktem F. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992, 1:488-91.
54. Hosoya M, Shigeta S, Mori S. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001, 45:943-5.
55. Anlar B, Aydin OF, Guven A, Sonmez FM, Kose G, Herguner O. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther 2004, 26:1890-4.
56. Takahashi T, Hosoya M, Kimura K. The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Res 1998, 37:29-35.
57. Hara S, Kimura H, Hoshino Y. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev 2003, 25:367-9.
58. del Toro-Riera M, Macaya-Ruiz A, Raspall-Chaure M, Tallada-Serra M, Pasqual-Lopez I, Roig-Quilis M. [Subacute sclerosing panencephalitis: combined treatment with interferon alpha and intraventricular ribavirin]. Rev Neurol 2006, 42:277-81. (In Spanish)
59. Otaki M, Sada K, Kadoya H, Nagano-Fujii M, Hotta H. Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference. Antiviral Res 2006, 70:105-11.
60. Titomanlio L, Soyah N, Guerin V. Rituximab in subacute sclerosing panencephalitis. Eur J Paediatr Neurol 2007, 11:43-5.
61. Panagariya A, Sureka RK, Aurora A. Current developments in the management of subacute sclerosing panencephalitis. J Assoc Physicians India 1998, 46:218-20.
62. Hayashi T, Ichiyama T, Nishikawa M, Furukawa S. Carbamazepine and myoclonus in SSPE subacute sclerosing panencephalitis. Pediatr Neurol 1996, 14:346.
63. Becker D, Patel A, Abou-Khalil BW, Pina-Garza JE. Successful treatment of encephalopathy and myoclonus with levetiracetam in a case of subacute sclerosing panencephalitis. J Child Neurol 2009, 24:763-7.